Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer

Journal of Pathology

Volumn 187, Issue 2, 1999, Pages 191-199

  Yazawa, Takuya ^a,b   Kamma, Hiroshi ^b   Fujiwara, Masachika ^c   Matsui, Miwa ^d   Horiguchi, Hisashi ^d   Satoh, Hiroaki ^b   Fujimoto, Mitsuo ^b   Yokoyama, Koichi ^a   Ogata, Takesaburo ^d  

^a Kensei General Hospital   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c UNIVERSITY OF TSUKUBA HOSPITAL   (Japan)

^d IBARAKI PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

Author keywords

Class II human leukocyte antigen; Class II transactivator; HLA DR; Non small cell lung cancer; Small cell lung cancer

Indexed keywords

GAMMA INTERFERON RECEPTOR; HLA DR ANTIGEN; RECOMBINANT GAMMA INTERFERON;

ANTIGEN EXPRESSION; ARTICLE; GENETIC TRANSCRIPTION; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION;

BLOTTING, NORTHERN; BLOTTING, SOUTHERN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; GENE EXPRESSION; HLA-DR ANTIGENS; HUMANS; INTERFERON-GAMMA, RECOMBINANT; LUNG NEOPLASMS; NUCLEAR PROTEINS; RNA, MESSENGER; TRANS-ACTIVATORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032938514     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199901)187:2<191::AID-PATH206>3.0.CO;2-3     Document Type: Article

References (42)

1. World Health Organization. Histological Typing of Lung Tumours. 2nd edn. Geneva: World Health Organization, 1981: 36.
2. Doyle A, Martin WJ, Funa K, et al. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med 1985; 161: 1135-1151.
3. Cole SPC, Campigotto BMT, Johnson JC, Elliott BE. Differential growth inhibition and enhancement of major histocompatibility complex class I antigen expression by interferons in a small-cell lung cancer cell line and its doxorubicin-selected multidrug-resistant variant. Cancer Immunol Immunother 1991; 33: 274-277.
4. Tanio Y, Watanabe M, Osaki T, et al. High sensitivity to peripheral blood lymphocytes and low HLA-class I antigen expression of small cell lung cancer cell lines with diverse chemo-radiosensitivily. Jpn J Cancer Res 1992; 83: 736-745.
5. Ostrand-Rosenberg S, Thakur A, Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 1990; 144: 4068-4071.
6. Basker S, Ostrand-Rosenberg S, Nabavi N, Nadler L, Freeman G, Glimcher LH. Constitutive expression of 87 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 1993; 90: 5687-5690.
7. Ostrand-Rosenberg S. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol 1994; 6: 722-726.
8. Hock RA, Reynolds BD, Tucker-McClung CL, Kwok WW. Human class II major histocompatibility complex gene transfer into m urine neuroblastoma leads to loss of tumorigenicity, immunity against subsequent tumor challenge, and elimination of microscopic pre-established tumors. J Immunother 1995; 17: 12-18.
9. Shastri N. Needles in haystacks: identifying specific peptide antigens for T cells. Curr Opin Immunol 1996; 8: 271-277.
10. Kamma H, Fujii K, Ogata T. Lymphocytic infiltration in juvenile thyroid carcinoma. Cancer 1988; 62: 1988-1993.
11. Yazawa T, Kamma H, Ogata T. Frequent expression of HLA-DR antigen in medullary carcinoma of the breast. A possible reason for its prominent lymphocytic infiltration and favorable prognosis. Appl Immunohistochem 1993; 1: 289-296.
12. Colloby PS, West KP, Fletcher A. Is poor prognosis really related to HLA-DR expression by malignant melanoma cells? Histopathology 1992; 20: 411-416.
13. Sheen-Chen SM, Chou FF, Eng HL, Chen WJ. An evaluation of the prognostic significance of HLA-DR expression in axillary-node-negative breast cancer. Surgery 1994; 116: 510-515.
14. Tsang SY, Nakanishi M, Peterlin BM. Mutational analysis of the DRA promoter: cis-acting sequences and trans-acting factors. Mol Cell Biol 1990; 10: 711-719.
15. Sloan JH, Hasegawa SL, Boss JM. Single base pair substitutions within the HLA-DRA gene promoter separate the functions of the X1 and X2 boxes. J Immunol 1992; 148: 2591-2599.
16. Reith W, Satola S, Herrero-Sanchez C, et al. Congenital immunodeficiency with a regulatory defect in MHC class II gene expression lacks a specific HLA-DR promoter binding protein. RF-X. Cell 1988; 33: 897-906.
17. Liou HC, Boothby MR, Finn PW, et al. A new member of the leucine zipper class of proteins that hinds to the HLA-DRα promoter. Science 1990; 247: 1581-1584.
18. Kara CJ, Liou HC, Ivashkiv LB, Glimcher LH. A cDNA for a human cyclic AMP response element-binding protein which is distinct from CREB and expressed preferentially in brain. Mol Cell Biol 1990; 10: 1347-1357.
19. Hooft van Huijsduijnen R, Li XY, Black D, Matthes H, Benoist C, Mathis D. Co-evolution from yeast to mouse: cDNA cloning of the two NF-Y (CP-1/CBF) subunits. EMBO J 1990; 9: 3119-3127.
20. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993; 75: 135-146.
21. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-γ mediated by the transactivator gene CIITA. Science 1994; 265: 106-109.
22. Riley JL, Westerheide SD, Price JA, Brown JA, Boss JM. Activation of class II MHC genes requires both the X box region and the class II transactivator (CHTA). Immunity 1995; 2: 533-543.
23. Murder RJ, Variakojis D, Silver J, Epstein AL. Immunohistochemical analysis of human lymphomas with monoclonal antibodies to B cell and Ia antigens reactive in paraffin sections. Lab Invest 1985; 52: 497-504.
24. Endo K, Kamma H, Ogata T. Two murine monoclonal antibodies against human lung cancer-associated antigens. Cancer Res 1986; 46: 6369-6373.
25. Matsumoto T, Teresaki T, Mukai K, et al. Relation between nucleolar size and growth characteristics in small cell lung cancer cell lines. Jpn J Cancer Res 1991; 82: 820-828.
26. Gazdar AF, Zweig MH, Carney DN, Van Steirteghen AC, Baylin SB, Minna JD. Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. Cancer Res 1981; 41: 2773-2777.
27. Carney DN, Gazdar AF, Bepler G, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985; 45: 2913-2923.
28. Lee JS, Trowsdale J, Travers PJ, et al. Sequence of an HLA-DR alpha-chain cDNA clone and intron-exon organization of the corresponding gene. Nature 1982; 299: 7511-752.
29. Ercolani L, Florence B, Denaro M, Alexander M. Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. J Biol Chem 1988; 263: 15 335-15 341.
30. Das HK, Laurance SK, Wekssman SM. Structure and nucleotide sequence of the heavy chain gene of HLA-DR. Proc Natl Acad Sci USA 1983; 80: 3543-3547.
31. Reith W, Herrero-Sanchez C, Kobr M, et al. MHC class II regulatory factor RFX has a novel DNA-binding domain and a functionally independent dimerization domain. Genes Dev 1990; 4: 1528-1540.
32. Aguet M, Dembic Z, Merllin G. Molecular cloning and expression of the human interferon-γ receptor. Cell 1988; 55: 273-280.
33. Son J, Donnelly RJ, Kotenko S, et al. Identification and sequence of an accessory factor required for activation of the human interferon γ receptor. Cell 1994; 75: 793-802.
34. Reith W, Barras E, Satola S, et al. Cloning of the major histocompalibility complex class II promoter binding protein affected in a hereditary defect in class II gene regulation. Proc Natl Acad Sci USA 1989; 86: 4200-1204.
35. Chang CH, Fontes JD, Peterlin M, Flavella RA. Class II transactivator (CIITA) is sufficient for the inducible expressoin of major histocompatibility complex class II genes. J Exp Med 1994; 180: 1367-1374.
36. Silacci P, Mottet A, Steimle V, Reith W, Mach B. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J Exp Med 1994; 180: 1329-1336.
37. Polak JM. Diagnostic Histopathology of Neuroendocrine Tumours. Edinburgh: Churchill Livingstone. 1993: 290.
38. Ucar K, Seeger RC, Challita PM, et al. Sustained cytokine production and immunophenotypic changes in human neuroblastoma cell lines transduced with a human gamma interferon vector. Cancer Gene Ther 1995; 2: 171-181.
39. Lennon A-M, Ottone C, Rigaud G, et al. Isolation of a B-cell-specific promoter for the human class II transactivator. Immunogenetics 1997; 45: 266-273.
40. Martin BK, Chin KC, Olsen JC, et al. Induction of MHC class I expression by the MHC class II transactivator CIITA. Immunity 1997; 6: 591-600.
41. Melief CJM, Offringa R, Toes REM, Kast WM. Peptide-based cancer vaccines. Curr Opin Immunol 1996; 8: 651-657.
42. Zier KS, Gansbacher B. IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells. J Mol Med 1996; 74: 127-134.